A “concerning doubling” in maternal deaths due to sudden unexpected death in epilepsy (SUDEP) was seen between 2016-18 compared to 2013-15, a new report has shown.
Stories about epilepsy
People with epilepsy should be included in the clinical risk group of people who should receive the COVID-19 vaccine early, according to provisional guidance from the government’s Green Book.
There is a slightly increased risk of hospital admission and death from COVID-19 in people with epilepsy, according to a new study in the British Medical Journal (BMJ).
The research, published in October 2020, looked at risk factors for hospital admissions and death from COVID-19 in 6.08 million adults across England. The data were collected between 24 January and 30 April.
International imagination icon Disney has advised that the latest Star Wars film could pose a seizure risk in people with photosensitive epilepsy.
The report, Epilepsy, a public health imperative, was released on Thursday 20 June, calling for action to improve healthcare and reduce stigma and discrimination.
Francesca’s epilepsy was very hard on her during her school years. Having become good at overcoming challenges, she decided to take on another one – get fit and run Tough Mudder
Epilepsy organisation Epilepsy Action has said it is disappointed with the lack of priority given to epilepsy in the NHS Long Term Plan.
The Long Term Plan was published on 7 January, detailing how the NHS intends to move healthcare forward over the next 10 years.
In a post, Epilepsy Action highlighted that while epilepsy is mentioned in the plan, it is not made a priority.
From today, specialist clinicians can prescribe cannabis-based medicines in the UK to patients with “exceptional clinical need”. They will no longer need to apply to an expert panel for a licence.
The UK government has rescheduled cannabis-based medicines under the Misuse of Drugs regulations 2001. They are now no longer listed under Schedule 1 alongside substances considered to have no therapeutic effect.
The Belfast Trust have announced that a further 1,044 patients previously seen by Consultant Neurologist Dr Michael Watt have been offered review appointments. The review appointments will ensure that these patients are on the correct treatment.
Around 2,500 patients previously under the care of Dr Watt were recalled earlier this year.